Elevated plasma levels of F2α isoprostane in cystic fibrosis

被引:69
作者
Collins, CE
Quaggiotto, P
Wood, L
O'Loughlin, EV
Henry, RL
Garg, ML
机构
[1] John Hunter Childrens Hosp, Dept Dietet, Rankin Pk, NSW 2305, Australia
[2] Univ Newcastle, Fac Med & Hlth Sci, Discipline Nutr & Dietet, Callaghan, NSW 2308, Australia
[3] New Childrens Hosp, Dept Gastroenterol, Sydney, NSW 2145, Australia
[4] Univ New S Wales, Sch Pediat, Sydney, NSW 2052, Australia
关键词
D O I
10.1007/s11745-999-0397-1
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Cystic fibrosis (CF) is associated with chronic lung infection, inflammation, and elevated indices of oxidative stress. Recently, isoprostanes were shown to be a reliable in vivo marker of oxidant injury with 8-iso-PGF(2 alpha), shown to cause airflow obstruction and plasma exudation in guinea pig lung. The present study was designed to examine the relationship between 8-iso-PGF(2 alpha), levels, plasma antioxidants, and clinical status in CF. We hypothesized that plasma 8-iso-PGF(2 alpha) levels would be higher in subjects with CF compared to healthy controls. Plasma 8-iso-PGF(2 alpha) levels were prospectively measured in 22 subjects with CF and nine healthy controls using an 8-isoprostane enzyme immunoassay kit along with plasma vitamins A, E, and p-carotene. Plasma 8-iso-PGF(2 alpha) levels were shown to be significantly elevated in the CF subjects compared to controls (319.6 +/- 52.6 vs. 145.0 +/- 21.0 pg/mL, P = 0.005). Plasma levels of antioxidants were significantly lower for the CF subjects compared to the controls (vitamin A, P < 0.003; vitamin E, P < 0.001; and beta-carotene, P < 0.01). This study confirms significantly elevated lipid peroxi--- dation in CF using 8-iso-PGF(2 alpha) levels.
引用
收藏
页码:551 / 556
页数:6
相关论文
共 37 条
[1]   Isoprostanes - Prostaglandin-like compounds formed in vivo independently of cyclooxygenase - Use as clinical indicators of oxidant damage [J].
Awad, JA ;
Roberts, JL ;
Burk, RF ;
Morrow, JD .
GASTROENTEROLOGY CLINICS OF NORTH AMERICA, 1996, 25 (02) :409-&
[2]   STATUS OF PLASMA AND ERYTHROCYTE FATTY-ACIDS AND VITAMIN-A AND VITAMIN-E IN YOUNG-CHILDREN WITH CYSTIC-FIBROSIS [J].
BIGGEMANN, B ;
LARYEA, MD ;
SCHUSTER, A ;
GRIESE, M ;
REINHARDT, D ;
BREMER, HJ .
SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY, 1988, 23 :135-141
[3]   CYSTIC-FIBROSIS, BREATH PENTANE, AND LIPID-PEROXIDATION [J].
BILTON, D ;
MADDISON, J ;
WEBB, AK ;
SEABRA, L ;
JONES, M ;
BRAGANZA, JM .
LANCET, 1991, 337 (8754) :1420-1420
[4]   PERSISTENT CHANGES IN THE FATTY-ACID COMPOSITION OF ERYTHROCYTE-MEMBRANES AFTER MODERATE INTAKE OF N-3 POLYUNSATURATED FATTY-ACIDS - STUDY DESIGN IMPLICATIONS [J].
BROWN, AJ ;
PANG, E ;
ROBERTS, DCK .
AMERICAN JOURNAL OF CLINICAL NUTRITION, 1991, 54 (04) :668-673
[5]   IS PENTANE A NORMAL CONSTITUENT OF HUMAN BREATH [J].
CAILLEUX, A ;
ALLAIN, P .
FREE RADICAL RESEARCH COMMUNICATIONS, 1993, 18 (06) :323-327
[6]  
CAMERON N, 1978, HUMAN GROWTH, V2
[7]   Current knowledge on fatty acids in cystic fibrosis [J].
Christophe, A ;
Robberecht, E .
PROSTAGLANDINS LEUKOTRIENES AND ESSENTIAL FATTY ACIDS, 1996, 55 (03) :129-138
[8]   Fat gram target to achieve high energy intake in cystic fibrosis [J].
Collins, CE ;
OLoughlin, EV ;
Henry, RL .
JOURNAL OF PAEDIATRICS AND CHILD HEALTH, 1997, 33 (02) :142-147
[9]  
DORING G, 1995, CYSTIC FIBROSIS, P99
[10]  
FUKUNAGA M, 1995, J CARDIOVASC PHARM, V26, pS51